Adaptive Biotechnologies Corp (NASDAQ: ADPT) is 14.90% higher on its value in year-to-date trading and has touched a low of $2.28 and a high of $5.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADPT stock was last observed hovering at around $5.75 in the last trading session, with the day’s loss setting it -0.12%.
Currently trading at $5.63, the stock is 14.05% and 17.59% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.77 million and changing -2.09% at the moment leaves the stock 43.61% off its SMA200. ADPT registered 16.80% gain for a year compared to 6-month gain of 58.15%. The firm has a 50-day simple moving average (SMA 50) of $4.7656 and a 200-day simple moving average (SMA200) of $3.912775.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 12.60% loss in the last 1 month and extending the period to 3 months gives it a 25.95%, and is 16.32% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.52% over the week and 6.25% over the month.
Adaptive Biotechnologies Corp (ADPT) has around 709 employees, a market worth around $830.27M and $168.77M in sales. Profit margin for the company is -126.49%. Distance from 52-week low is 146.93% and -2.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-46.60%).
The EPS is expected to grow by 22.02% this year
242.0 institutions hold shares in Adaptive Biotechnologies Corp (ADPT), with institutional investors hold 101.64% of the company’s shares. The shares outstanding are 145.08M, and float is at 142.33M with Short Float at 6.66%. Institutions hold 99.68% of the Float.
The top institutional shareholder in the company is VIKING GLOBAL INVESTORS LP with over 29.99 million shares valued at $108.58 million. The investor’s holdings represent 20.5736 of the ADPT Shares outstanding. As of 2024-06-30, the second largest holder is RUBRIC CAPITAL MANAGEMENT LP with 14.0 million shares valued at $50.68 million to account for 9.603 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.66 million shares representing 8.0007 and valued at over $42.22 million, while MATRIX CAPITAL MANAGEMENT COMPANY, LP holds 7.938 of the shares totaling 11.57 million with a market value of $41.89 million.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
The most recent transaction is an insider sale by Taylor Stacy L, the company’s SVP and General Counsel. SEC filings show that Taylor Stacy L sold 26,922 shares of the company’s common stock on Aug 22 ’24 at a price of $4.50 per share for a total of $0.12 million. Following the sale, the insider now owns 0.14 million shares.
Still, SEC filings show that on Mar 05 ’24, PISKEL KYLE (Principal Accounting Officer) disposed off 7,727 shares at an average price of $3.43 for $26504.0. The insider now directly holds 123,318 shares of Adaptive Biotechnologies Corp (ADPT).
